• Predictive siRNA Codelivery with Netarsudil

  2026-09-14

  Slaughter et al. developed a quantitative framework that links ionizable-drug structure to siRNA complexation and nanoparticle encapsulation. The study identified Netarsudil as a high-performing candidate and demonstrated CTGF siRNA codelivery with reduced CTGF expression and actin-network density in fibrotic human trabecular meshwork cells.

• Trichostatin A (TSA): Mechanism and Research Use

  2026-09-14

  Trichostatin A (TSA) is a reversible histone deacetylase inhibitor used to study chromatin acetylation, differentiation, and cancer biology. Its research value comes from reproducible histone hyperacetylation and context-dependent effects on proliferation, cell-cycle progression, and combination treatment responses.

• BX795: From Kinase Potency to Translational Signal

  2026-09-13

  BX795 is more than a potent PDK1 inhibitor: its simultaneous activity toward PDK1, TBK1, and IKKε creates an opportunity to connect kinase engagement with cancer phenotypes and innate immune signaling. This article outlines a translational workflow that separates pathway inhibition, cytostasis, and cell death while defining where BX795 is informative—and where its polypharmacology requires caution.

• ATG4B Nuclear Translocation Drives AML Instability

  2026-09-12

  A 2025 Advanced Science study identifies energy deficiency-induced nuclear translocation of ATG4B as a direct inhibitor of PRMT1-dependent DNA repair in acute myeloid leukemia. The work links metabolic stress to MRE11 methylation, genomic instability, leukemia progression, and therapeutic vulnerability through complementary cellular, mouse, and patient-derived models.

• Silybin A: Reproducible Silymarin Workflows

  2026-09-11

  Build solvent-aware, stereochemically defined assays for oxidative stress reduction, inflammatory signaling, and liver injury models with Silybin A rather than an incompletely characterized botanical mixture. This practical guide covers stock preparation, dosing, analytical controls, and troubleshooting for hepatoprotective and metabolic studies.

• Annexin V-FITC/PI Apoptosis Assay Kit Workflow

  2026-09-11

  Turn phosphatidylserine externalization and membrane integrity into a practical, single-cell readout for renal cancer drug studies. This workflow shows how to use the Annexin V-FITC/PI Apoptosis Assay Kit to separate viable, early apoptotic, late apoptotic, and necrotic populations while avoiding common interpretation and staining errors.

• FAISL–FAK Proteolysis in Triple-Negative Breast Cancer

  2026-09-10

  The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its combination of transcriptomic analysis, RNA–protein interaction mapping, functional assays, and nanoparticle-mediated FAISL silencing defines a mechanistic and potentially actionable regulatory axis.

• Lapatinib Beyond HER2: A Translational Playbook

  2026-09-10

  Lapatinib, also known as GW572016, offers a disciplined bridge from EGFR and HER2 kinase inhibition to proliferation, invasion, and angiogenesis phenotypes. This translational framework shows how to use biochemical potency, receptor context, and phenotype-first models without overstating target engagement.

• EZ Cap Cy5 Firefly Luciferase mRNA: Assay Design

  2026-09-09

  EZ Cap Cy5 Firefly Luciferase mRNA enables a state-resolved view of mRNA delivery, intracellular localization, and productive translation. This article explains how to interpret paired Cy5 and luciferase signals, using formulation evidence to improve assay decisions rather than simply adding another reporter.

• γH2AX DNA Damage Detection Kit Workflow Guide

  2026-09-09

  Learn how to apply the γH2AX DNA Damage Detection Kit to DNA double-strand break detection, repair kinetics, genotoxicity assessment, and radiation-response studies. The workflow emphasizes quantitative imaging, assay controls, and practical troubleshooting for cell and tissue experiments.

• ATG4B Nuclear Translocation Drives AML DNA Repair Failure

  2026-09-08

  The 2025 Advanced Science study identifies an energy-sensitive ATG4B–PRMT1–MRE11 pathway that links metabolic stress to defective DNA repair and acute myeloid leukemia progression. Its combination of mechanistic, cellular, mouse, and patient-derived models suggests that ATG4B inhibition may restore DNA damage responses and constrain malignant evolution, while also defining important limits for translation beyond AML.

• Nanozymes Target Intramacrophage Bacteria in CRC

  2026-09-08

  The 2026 ACS Nano study develops a mannose-targeted, self-activating polymeric nanozyme that uses intracellular hydrogen peroxide to generate bactericidal reactive oxygen species against Fusobacterium nucleatum residing in tumor-associated macrophages. By combining bacterial clearance with macrophage reprogramming, the platform substantially improves the response to CD47 blockade in colorectal cancer models.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-07

  The Annexin V-FITC/PI Apoptosis Assay Kit uses calcium-dependent phosphatidylserine binding and membrane-impermeant PI uptake to separate viable, early apoptotic, late apoptotic, and necrotic cell populations. The K2003 workflow supports rapid 10–20-minute cell-based apoptosis assay readouts by flow cytometry or fluorescence microscopy, but marker patterns require biological controls and should not be treated as diagnostic evidence.

• ATG4B Links Energy Deficiency to AML Progression

  2026-09-07

  The reference study identifies energy deficiency-induced nuclear translocation of ATG4B as a mechanism that suppresses PRMT1-dependent MRE11 methylation, weakens DNA repair, and promotes genomic instability in acute myeloid leukemia. Its combination of mechanistic cell biology, leukemia models, and patient-derived xenografts suggests that ATG4B inhibition may constrain malignant evolution rather than merely reduce short-term proliferation.

• D-Luciferin Sodium Salt for CAR-M Assays

  2026-09-05

  D-Luciferin sodium salt enables ATP-dependent bioluminescence assays that distinguish cellular abundance from functional activity in CAR-macrophage research. This guide translates the chemistry into practical assay design, controls, and interpretation for oncology studies.

7642 records 1/510 page Next 12345 下5页 Last page